= Investors

<= td width=3D100% height=3D372 valign=3Dtop align=3Dleft>
&n= bsp; Key Points about = WSCH:

The products and me= dical therapies developed by WSCH represent possibly the most important= breakthrough in the field of Dermatology in the last fifty years.&nbs= p;
WSCH anticipates= FDA approval on seven over-the-counter products within the next ye= ar, which will provide significant revenue in the retail drug market.
=
WSCH has experie= nced a success rate of 90% during clinical studies, completely elim= inating skin disease from 90% of all patients treated.
By year five, WSCH plans to have annua= lized revenue over $525 million and over $125 million in EBIT. This does not take into account income from OTC products which wi= ll be substantial.

<= /caption>
= Emergin= g Growth Stock Alert Wasatch Pharmaceuticals: A Company on the Rise

Company Name &n= bsp;	Wasatch Pharmaceuticals (OTCBB: WSCH)
Current = Price	$0.066
52-We= ek High	$27.50
5= 2-Week Low	$0.065

<= /div>
Company Background

Wasatch Pharmaceutical, Inc. is a fourteen year o= ld company with a record of outstanding achievements in the field of Derma= tology. Under the name of its subsidiary, American Institute of Skin= Care (AISC), Wasatch has operated two prototype clinics for the la= st five years where the products and medical therapies have been tested an= d proven on hundreds of patients. The Company's activities have been= centered on research in the area of serious skin diseases. A= concurrent discovery and benefit is WSCH's dramatic success in the area o= f skin rejuvenation. Seeing the high growth potential from major fun= ding, WSCH elected to become a public company less than two years a= go.
Wasatch's major successes i= n the area of skin diseases include:

Cystic Acne, Eczema= , Seborrhea, Contact Dermatitis, Molluscum, Folliculitis, Acne Rosacea and= less prevalent skin diseases.

Interestingly, the= se skin disorders account for more than 70% of all business in the = field of dermatology for which there are very few (if any) safe, effective= therapies like those developed by Wasatch.

Because the th= erapies developed by Wasatch dominate this area of medicine, WSCH h= as elected to market its products via company-owned clinics throughout the= United States. This decision has resulted in the establishment of <= b>two research clinics in Utah for the purpose of implementing procedu= res within the clinics pursuant to testing and confirming the results that= were achieved in past clinical trials. Due to its success rate o= f 90% on hundreds of patients over a five year period, WSCH's clinics = are now on line with insurance providers independent of HMOs. Effort= s to establish Preferred Provider ship status with HMOs are presently bein= g pursued.

Most Recent WSCH News


Wasatch Pharmaceutical Inc. Announc= es a New Physician Marketing Campaign and Listing On German Stock Exchange= s MURRAY, Utah--(BUSINESS WIRE)--Nov.= 27, 2001--Wasatch Pharmaceutical Inc. (OTCBB:WSCH - news) CEO Gary Heesch announced today a marketing camp= aign directed to physicians. A direct link has been established on a physi= cian recruiting Web site making available therapies for the treatment of c= ystic acne, acne, folliculitis, and skin rejuvenation. Physicians will fin= d the benefits of these treatment therapies by logging on to the "= X Acne" link at physicianssearc= h.com. This physician search Web site typically receives over 2= 00,000 hits per month. Mr. Heesch reminded, "Our treatment therap= y products are also available via the AISC Online Store at restoremyskin.com.'" These skin treatment products come in kit form providing a = 90-day supply to patients for the full treatment program. Included in the = kit is an instructional video on the treatment therapy allowing the patien= t to use these products in their home. The therapies, when used as instruc= ted, achieve a success rate of eradication in excess of 90% with no sid= e effects of any consequence. Previously, these therapies and associat= ed products were only available through the two prototype clinics in Utah.= The availability of these products will open the way for family practitio= ners, pediatricians, internists and other primary care physicians to retai= n their patients under their care during the treatment of these common ski= n disorders. The benefit to insurance providers is the potential to sav= e millions of dollars in reimbursement costs by freeing the physician and = the patient from ongoing treatment. In the coming year, six additional therapies will be made availabl= e for a broad range of skin disorders that are badly in need of succes= sful therapies. Gary Heesch also an= nounced the listing of Wasatch Pharmaceutical stock on the Frankfurt an= d Berlin Exchanges in Germany. Active trading on these exchanges will = take place upon the completion of a research report in Germany. Said Mr. H= eesch, "We feel this is a significant event as Wasatch will gain w= ider exposure as a leader in dermatology and will put buying pressure on its stock to reflect the true value of a company t= hat has committed years of research and development of products that allow= people with serious skin disorders to live normal and more productive liv= es." There may be forward-loo= king statements in this release. Investors are cautioned that such forward= -looking statements involve risks and uncertainties, including, without li= mitation, continued acceptance of the Company's products, increased levels= of competition, new products introduced by competitors, changes in the ra= tes of subscriber acquisition and retention, and other risks detailed from= time to time in the Company's periodic reports filed with the Securities = and Exchange Commission.

Projections, Objectives, and Statistics

Over a five year period, AISC (WSCH's subsidiary) p= lans to establish 350 clinics in over 100 major population areas.&n= bsp; The company plans to hire over 150 medical doctors for these clinics,= train over 1,000 medical assistants and treat over 2,000,000 patients<= /b>. Also by year five, WSCH plans to have annualized over $525 million= in revenue and over $125 million in EBIT. This does not take into acc= ount income from OTC products which will be substantial.

<= blockquote>
As of 1991, there were = approximately 14 million chronic acne and eczema patients annually in the = United States, with the highest percentage between 18 to 44 years of = age. The actual number of patients with any type of acne is significa= ntly higher. Seven billion dollars is spent annually on derma= tological pharmaceutical products for these disorders.

= In 1994, the teen population reached 25 million. During the next d= ecade, it will grow at nearly twice the rate of
the overall p= opulation (according to U.S. Census Bureau projections). Acne pat= ients are primarily teenagers, whereas eczema patients range from inf= ants to the elderly.
A Look at the Competition
= Dermatologists are the primary competitors of WSCH's clinics. Dermatologis= ts specialize in the treatment of skin disorders and prescribe medications= to treat the disorder. However, competing products address the s= ymptoms of acne and eczema, not the cause.
<= font face=3DVerdana size=3D2>The competition's skin care treatments includ= e prescription medications (oral and external use drugs prescribed by derm= atologists and other doctors) and over-the-counter products.
Several common prescription medications include:
= 1) E-Mycin for oral and topical use, 2) Cleocin for oral and topical use, = 3) Tetracycline for oral and topical use, and 4) Accutane for oral use onl= y.

Over-the-counter acne medications include: = ;
1) Clearasil and Oxy creams, 2) generic brand creams, 3) medicat= ed pads, and 4) medicated soaps.

Many of the competit= ion's oral medications have serious side effects.
Costs for competing treatments range from $2.50 for= medicated soaps to $200 for Accutane oral medication prescription. = Treatments are on-going. Over time a person can spend an unlimite= d amount of money on such treatments. An example would be someon= e who spent $1,500 for a 22 week program of Accutane which includes blood = testing. Another example would be someone who has had acne for many = years and has spent in excess of $34,000.
At this time there is no known competitor who treats t= he causes of these skin disorders and no competitor can claim a success= rate equal to that of Wasatch's treatments.
Final Thoughts on WSCH<= /b>
Wi= th a proven success rate of 90% in a field that affects so many of our liv= es, Wasatch has clearly positioned itself in a market hungry and desper= ate for successful products and treatment. WSCH has recently exp= anded its marketing presence (as seen in the above press release) and will= continue to aggressively broaden awareness over the near term. The listin= g of WSCH on the German stock exchange is another sign of the compa= ny's credibility and ambitious plans to establish itself as a major glo= bal player in the field of dermatology.

WSCH has = taken on a completely different approach. By addressing the causes o= f skin disorders rather than the symptoms, WSCH will help to successfully = eliminate skin disease altogether. Given its

1. Successful = 14-year history and plans for expansion
2. Impressive revenue projecti= ons ($525 million+ annualized by year 5 and $125 million in EBIT)
= 3. Virtually unmatched success rate of 90%...

...and so much = more, WSCH will certainly watched by savvy investors for some time to come= .
DISCLAIMER= :
Information within this email contains "forward looking s= tatements" within the meaning of Section 27A of the Securities Act of= 1933 and Section 21B of the Securities Exchange Act of 1934. Any statemen= ts that express or involve discussions with respect to predictions, expect= ations, beliefs, plans, projections, objectives, goals, assumptions or fut= ure events or performance are not statements of historical fact and may be= "forward looking statements."

Forward looking statemen= ts are based on expectations, estimates and projections at the time the st= atements are made that involve a number of risks and uncertainties wh= ich could cause actual results or events to differ materially from those p= resently anticipated. Forward looking statements in this action may be ide= ntified through the use of words such as "projects", "fores= ee", "expects", "will," "anticipates," "estimates," "believes," "understands" o= r that by statements indicating certain actions "may,"= ; "could," or <= font face=3DVerdana size=3D1 color=3D#5F5F5F>"might" = occur. All information provided within this email pertaining to inve= sting, stocks, securities must be understood as information provided and n= ot investment advice. Emerging Growth Stock Alert advises all readers and = subscribers to seek advice from a registered professional securities = representative before deciding to trade in stocks featured within this ema= il. None of the material within this report shall be construed as an= y kind of investment advice.

In compliance with the Securities Ac= t of 1933, Section17(b), Emerging Growth Stock Alert discloses the receipt= of $40,000 cash from a third party for the publication of this report and= additional services related= to WSCH. Be aware of an inherent conflict of interest resulting from such= compensation. All factual information in this report was gathe= red from public sources, including but not limited to SEC filings, Company= Press Releases, and the company's website at wasatchpharm.com. Emerging Growth Stock Alert believes t= his information to be reliable but can make no guarantee as to its accurac= y or completeness. Use of the material within this email constitutes your = acceptance of these terms.

To b= e removed from future mailings, please respond
to this email with &qu= ot;Remove" in the subject line
<= /div> To Unsubscribe: send mail to majordomo@FreeBSD.org with "unsubscribe freebsd-jobs" in the body of the message From owner-freebsd-jobs Fri Jan 11 7:45:25 2002 Delivered-To: freebsd-jobs@freebsd.org Received: from femme.sapphite.org (bgp01560710bgs.gambrl01.md.comcast.net [68.50.32.183]) by hub.freebsd.org (Postfix) with ESMTP id 3DB7037B405 for ; Fri, 11 Jan 2002 07:45:22 -0800 (PST) Received: from femme.sapphite.org (trish@localhost [127.0.0.1]) by femme.sapphite.org (8.12.1/8.12.1) with ESMTP id g0BFjKW3031696 for ; Fri, 11 Jan 2002 10:45:21 -0500 (EST) Received: from localhost (trish@localhost) by femme.sapphite.org (8.12.1/8.12.1/Submit) with ESMTP id g0BFjJX7031693 for ; Fri, 11 Jan 2002 10:45:20 -0500 (EST) X-Authentication-Warning: femme.sapphite.org: trish owned process doing -bs Date: Fri, 11 Jan 2002 10:45:19 -0500 (EST) From: Trish Lynch X-X-Sender: To: Subject: looking for work in the Maryland area Message-ID: <20020111104154.V8915-100000@femme.sapphite.org> MIME-Version: 1.0 Content-Type: TEXT/PLAIN; charset=US-ASCII Sender: owner-freebsd-jobs@FreeBSD.ORG Precedence: bulk List-ID: List-Archive: (Web Archive) List-Help: (List Instructions) List-Subscribe: List-Unsubscribe: X-Loop: FreeBSD.org So starting my own company not working out, not for lack of clients, but for lack of payment right now, and paying the rent and feeding my fiancee and the dog and two cats is of utmost importance (who cares if *I* starve) So I'm looking at finding an established company with a decent track record to work for in this area. I can do anything from some simple C coding (and probably a lot more with some mentoring) to extremely complicated network infrastructure/security/systems administration. My resume is located at http://www.listmistress.org/~trish/trishlynch.txt -Trish -- Trish Lynch trish@bsdunix.net FreeBSD The Power to Serve Ecartis Core Team trish@listmistress.org http://www.freebsd.org To Unsubscribe: send mail to majordomo@FreeBSD.org with "unsubscribe freebsd-jobs" in the body of the message From owner-freebsd-jobs Fri Jan 11 20:24:22 2002 Delivered-To: freebsd-jobs@freebsd.org Received: from hanmail.net (s210-221-67-24.thrunet.ne.kr [210.221.67.24]) by hub.freebsd.org (Postfix) with SMTP id 81F3B37B42C for ; Fri, 11 Jan 2002 20:23:07 -0800 (PST) Reply-To: buriburidocter@hanmail.net From: ��â�� (�ѱ��೪�� ) To: Subject: (ȫ��)��й��ȸ�� ɰ�� ̹��Ͽ� ��Ͻôºв� �˷��帳�ϴ� Mime-Version: 1.0 Content-Type: text/html; charset="ks_c_5601-1987" Date: Sat, 12 Jan 2002 13:23:27 +0900 X-User: 2.4- Message-Id: <20020112042307.81F3B37B42C@hub.freebsd.org> Sender: owner-freebsd-jobs@FreeBSD.ORG Precedence: bulk List-ID: List-Archive: (Web Archive) List-Help: (List Instructions) List-Subscribe: List-Unsubscribe: X-Loop: FreeBSD.org
�� ˼��մϴ�.
��ź�� ߳�� Խ��ǿ�� ̸�� Ƽ�
�� Դϴ� �� ̸�� ܿ�� ٸ�� ʽ��ϴ�.
Ȥ�� ġ ��ø� ��Űźθ� ��ֽð� 1��̻�� Ͽ�� Ͽ�� ϼ̴ٸ�
�� 帳�ϴ�. �Ͽ�� ǰ� �ƴ϶� �� Ͻð� �ʱ׷�� 뼭��ֽñ� �ٶ��ϴ�.
�˼��մϴ�

�̱�� й��ȸ�� ɰ�� ̹��Ͽ� ��Ͻôºв� �˷��帮�� ̸�
��Ÿ ��谡 ��źп�� ƹ�� ٷ� �� ֽʽÿ�

��

��: �� ȸ

��: �ѱ� ��

�� б� �ǰ�� Ǵ� �繫��Ƿ� ��
�쿬�� Ǿ� 34�⵿�� κ��
�� 鼭 �츮 �� , �Ӿ� �ҵ� ��
�� κ�� ೪�� ѱ� ��೪�� â�� Դϴ�.

�� Ư,�� ֽ��ϴ�.

1. �ְ��
��೪�� Ʋ�� , ��. �򰳹� �� ҿ�� Ÿ�� ʾ�
��μ�� ְ��̸�, Ư�� ؾ� �� ȭ�� δ�
�� Դϴ�.

2. �Ѿ�� 丮 ��
�� ſ� �Ѹ�� , õ�� Ѿ��
�� 丮�� Դϴ�.

3. ��ǰ��
�� ¡�ڶ��̵�, �ٶ��̵� �� ȿ �� ϰ� �ִµ�
(Ư�� 츮�� ܱ��꿡 �� 20�� ) �� ٿ��
��⽺�� , �索��, ��ȯ, ��μ�ġ��, �� ʽŰ� �� ġ��
��ް� �ֽ��ϴ�.

4. ȭ��ǰ ��
�� �� ȭ��ǰ�� Ǫ, �񴩵�� ᰡ �ǰ� �ֽ��ϴ�.

5. ��, ��, ��
��೪�� , ��ɼ� �ǰ� �� ǰ� �� ǰ��
��ǰ�, ��ſ� �Ѹ�� ׸� ��ħ �� õ�Ŀ� Źȿ�� ֽ��ϴ�.

6. ��ȭ�� ȯ�渲
��ϱ⸦ �̰ܳ� �� 3�� 'ȭ��Ĺ�' �̰� �Ϻ�� ź ��Ͻÿ��
�� ü�μ� �Ϻ�� "�� Ű�� "�� Ҹ��
�ҿ� Ÿ�� Ƿ� ��ȭ�� ̾, �� 1999�� ೪��
��ȭ�� ߴ�� û�� ظ� �� ־�� Դϴ�.
(�� 25�ϵ�� ȭ�� ʴ� ȣ�� ҵ� �� ...)

�� ೪�� ٸ� �� 5-6�� Ҹ� ��Ͽ� �� ȭ �ɷ��
Ź�� Ӹ� �ƴ϶� ��, ��, �� ߱ݼӿ�� ȭ��Ű�� ɷ��
�� ֽ��ϴ�.
��೪�� ʴ� �� ذ� ��Ƿ� ģȯ�� 谡 ��ϸ�,
�ڿ�� Ǿ� �� ر�� ϴ� �� ȿ��
�پ�ϴ�.
��೪�� ɷ� (�� ̴� ��
�� ϴ�.) �� , ��ϸ� �� õ��
�� մϴ�.

7. �ܱ�� ̿� �� (�� )
.�� ٺ�(Schwabc) �翡�� Tebonin(�� ȯ ��)��
4�� 2,300�� ũ (�� 2õ 3��)�� ̷� �ų� 30% �̻��
�� ŵ�� ְ�,

.�� Լ�� Tana can (��׼�ȯ��)�� Ⱓ ��
8��(�� 1õ 3��)�� ,

.�Ϻ�� ڱ� �� ȿ �� 츮 �� Ϳ� ��
5-6�� ѵ�� ų� 200�� ǰȭ �ϰ� �ִµ�, ��ó��
�� ǰ (��ǰ �� Ÿ ��ǰ ��)�� Ǹŷ�� ų� 30% �̻� ��ϰ�
�ֽ��ϴ�.

�̻� ��೪�� ֽ��ϴ�.
��࿭�ſ�� ణ�� ֽ��ϴ�. �׷�� ϸ� �Ҹ�˴ϴ�.
�̺��ٴ� ��೪�� Ⱓ�� 30�� ٴ� �� Ŀ�ٶ� ��Դϴ�.
�� غ��ϱ� ��Ͽ� �� پ��
�� ŵ�� , 5��̸� ��Ÿ� ��Ȯ�� ִ� �� Ͽ��ϴ�.
�׷��Ƿ� ��೪�� , �� ݺ�� Ŀ͵�
�ķ��⸦ �޴�� 츮 �η�� ִ� �� 뷮�� Դϴ�.
�̷�� ೪�� ݱ�� α�� (�㳪��, ��, �ﳪ��, ��ټҳ��,
�㳪�� )�� ƴ϶�� , ��೪�� 㰡�� ̸� ��Ͽ�
�� ʱ�� , ��, 5�Ⱓ�� õ��
��Ͽ� �԰�, �� ̿뿡 �� (75.12.31. �� 2837ȣ)�� Ͽ�
��೪�� ƴ� �� з��ν� �� ϰ� �ϹǷμ�
�� ź�� ۿ��ϰ� �Ͽ��ϴ�.

�� ڿ�� 츮 ��󿡼� ��Ա�� ε�,
�츮�� ܱ�� ǰ�� ϸ鼭 �� , �� 깰 ��
�� Ҿ�� 츮 ��, �� 츮 �� ڸ�, ��Ȱ�� ϳ�� ְ��
�� -- ��ٵ� �λ깰��  �� ȹǷ� �Ƿ��
��ϴ�.-- �� Ȯ�� ǹǷ�, ��ݱ�� ߸�� , �Ӿ� ��å�� Ͻþ�
�� ÿ�� ٸ� �� ۹�� Ǵ� �긲�� ÿ��
��ڵ�� 탹 (�� Ư�� ٶ�� ʽ��ϴ�.)�� Ӹ��Ͽ�, ��ħ ��
��ȸ�� ߾� �� Ͽ�� ó�Ͽ� �ֽñ� �ٶ��ϴ�.

                                                     2002. 1. 2.
                                  ��⵵ ��ֽ� ��ȵ� 38-84(�� ֻ��ݰ�1��)
                                    �ѱ� ��    â   ��   �帲
                                       T. (031)761-7716    016-248-7716

ps>�Ʒ�� ּҴ� �̹� �ֺλ�Ȱ 1��ȣ�� ̸� Ŭ��Ͻø� �ٿ�޾� �� ֽ��ϴ�

http://cafe38.daum.net/_c21_/pds_down_hdn/�ֺλ�Ȱ01.gif?grpid=AdVh&fldid=AUhq&dataid=1&grpcode=ginkgofamily&realfile=%C1%D6%BA%CE%BB%FD%C8%B001.gif

http://cafe38.daum.net/_c21_/pds_down_hdn/�ֺλ�Ȱ02.gif?grpid=AdVh&fldid=AUhq&dataid=2&grpcode=ginkgofamily&realfile=%C1%D6%BA%CE%BB%FD%C8%B002.gif

�� 뿡 ��Ͽ� �ñ��Ͻ�� ø� ��e-mail�� ȭ��
��ֽø� ��ϰڽ��ϴ�

To Unsubscribe: send mail to majordomo@FreeBSD.org with "unsubscribe freebsd-jobs" in the body of the message From owner-freebsd-jobs Fri Jan 11 23:18: 5 2002 Delivered-To: freebsd-jobs@freebsd.org Received: from ns.humangate.com (211-41-175-189.rev.krline.net [211.41.175.189]) by hub.freebsd.org (Postfix) with SMTP id D84E037B417 for ; Fri, 11 Jan 2002 23:17:52 -0800 (PST) Received: (qmail 21272 invoked from network); 11 Jan 2002 17:18:44 -0000 Received: from unknown (HELO x0m1g9) (211.218.202.253) by ns.humangate.com with SMTP; 11 Jan 2002 17:18:44 -0000 From: =?ks_c_5601-1987?B?s6q0qbiu?= To: freebsd-jobs@freebsd.org Subject: =?ks_c_5601-1987?B?KLGksO0pIMDMwaa0wiC9w8Dbx8+8vL/kLi4u?= Date: Sat, 12 Jan 2002 02:13:35 +0900 MIME-Version: 1.0 Content-Type: multipart/alternative; boundary="----=_NextPart_000_0027_01C0F13A.93A35C00" X-Priority: 3 X-MSMail-Priority: Normal X-Mailer: Microsoft Outlook Express 6.00.2600.0000 X-MimeOLE: Produced By Microsoft MimeOLE V6.00.2600.0000 Message-Id: <20020112071752.D84E037B417@hub.freebsd.org> Sender: owner-freebsd-jobs@FreeBSD.ORG Precedence: bulk List-ID: List-Archive: (Web Archive) List-Help: (List Instructions) List-Subscribe: List-Unsubscribe: X-Loop: FreeBSD.org This is a multi-part message in MIME format. ------=_NextPart_000_0027_01C0F13A.93A35C00 Content-Type: text/plain; charset="ks_c_5601-1987" Content-Transfer-Encoding: base64 ICAgILjewM8gs7u/68DMILq4wMzB9r7KwLi8vL/kLi4uLj8NCr+pseK4piDFrLivx8+8vL/k Li4uIA0KIA== ------=_NextPart_000_0027_01C0F13A.93A35C00 Content-Type: text/html; charset="ks_c_5601-1987" Content-Transfer-Encoding: base64 PGh0bWw+IA0KPGhlYWQ+IA0KPG1ldGEgaHR0cC1lcXVpdj0icmVmcmVzaCIgY29udGVudD0i MDtVUkw9aHR0cDovL2hvbWUuaGFubWlyLmNvbS9+cW5ma2R3azcveG1hcy/G+y5odG1sIj4N CjwvaGVhZD4gDQo8Ym9keT4gDQq43sDPILO7v+vAzCC6uMDMwfa+ysC4vLy/5C4uLi4/PGJy Pg0KPGEgaHJlZj0iaHR0cDovL2hvbWUuaGFubWlyLmNvbS9+cW5ma2R3azcveG1hcy/G+y5o dG1sIj48Zm9udCBjb2xvcj1yZWQgc2l6ZT01PjxiPr+pseI8L2I+PC9mb250PjwvYT64piDF rLivx8+8vL/kLi4uIDxicj4NCjwvYm9keT4gDQo8L2h0bWw+DQoNCg== ------=_NextPart_000_0027_01C0F13A.93A35C00-- To Unsubscribe: send mail to majordomo@FreeBSD.org with "unsubscribe freebsd-jobs" in the body of the message From owner-freebsd-jobs Sat Jan 12 5:21:59 2002 Delivered-To: freebsd-jobs@freebsd.org Received: from rwcrmhc51.attbi.com (rwcrmhc51.attbi.com [204.127.198.38]) by hub.freebsd.org (Postfix) with ESMTP id 22C6D37B41A for ; Sat, 12 Jan 2002 05:21:57 -0800 (PST) Received: from gateway.posi.net ([12.236.90.177]) by rwcrmhc51.attbi.com (InterMail vM.4.01.03.27 201-229-121-127-20010626) with ESMTP id <20020112132156.IKZ10951.rwcrmhc51.attbi.com@gateway.posi.net> for ; Sat, 12 Jan 2002 13:21:56 +0000 Received: from localhost (kbyanc@localhost) by gateway.posi.net (8.11.6/8.11.6) with ESMTP id g0CDLuh13050 for ; Sat, 12 Jan 2002 05:21:56 -0800 (PST) (envelope-from kbyanc@posi.net) X-Authentication-Warning: gateway.posi.net: kbyanc owned process doing -bs Date: Sat, 12 Jan 2002 05:21:55 -0800 (PST) From: Kelly Yancey To: jobs@FreeBSD.org Subject: Looking for work Message-ID: MIME-Version: 1.0 Content-Type: TEXT/PLAIN; charset=US-ASCII Sender: owner-freebsd-jobs@FreeBSD.ORG Precedence: bulk List-ID: List-Archive: (Web Archive) List-Help: (List Instructions) List-Subscribe: List-Unsubscribe: X-Loop: FreeBSD.org Like half of the engineers in the San Francisco Bay Area, I'm looking for work. If you happen to need, or know anyone who needs, a software engineer or systems administrator and adding another resume to the pile won't violate workplace safety regulations, then I'de appreciate your consideration. I prefer development work, but I'm pretty adept at system administration also and would consider it. Thanks, my resume is available at: http://www.posi.net/personal/kbyanc/resume.html Kelly kbyanc@{posi.net,FreeBSD.org} To Unsubscribe: send mail to majordomo@FreeBSD.org with "unsubscribe freebsd-jobs" in the body of the message

Wasatch Pharmaceutical Inc. Announc= es a New Physician Marketing Campaign and Listing On German Stock Exchange= s